Targeted Oncology Staff

During a live virtual event, Alicia Morgans, MD, MPH, discussed the choice of novel hormonal agents to combine with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer.

Rachel B. Salit, MD, discussed the case of a 48-year-old patient with graft-versus-host-disease.

A 51-year-old man presented with worsening fatigue on exertion and pallor, with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options in patients with chronic lymphocytic leukemia.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was later diagnosed with advanced stage non–small cell lung cancer.

During a live virtual event, Alicia Morgans, MD, MPH, discusses the appropriate usage of new genetic testing and PSMA scans in nonmetastatic castration-resistant prostate cancer.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options of BTK inhibitors in patients with chronic lymphocytic leukemia.

Tanya Dorff, MD, asks the participants of a roundtable discussion about their opinion survival data of androgen receptor–targeted therapy and treating patients with PET scan-only metastatic castration-resistant prostate cancer.

A 75-year-old patient with metastatic castration resistant prostate cancer experienced an increase hip pain and urinary frequency 12 months after external beam radiation therapy plus androgen deprivation therapy.

Twelve months following a thyroidectomy with bilateral central neck dissection and later declining systemic therapy, a 58-year-old man with medullary thyroid cancer was no longer asymptomatic.

How an oncologist treats a patients with non–small cell lung cancer wit the available treatment options is largely dependent on the patient's PD-L1 status.

The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

Tanya Dorff, MD, asks the participants of a roundtable discussion which novel hormonal therapy they would choose in a patient with nonmetastatic castration-resistant prostate cancer.

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians the treatment options for patients with chronic lymphocytic leukemia in the front-line setting by risk assessment.

A 51-year-old man presented with pallor and worsening fatigue on exertion and was diagnosed with multiple myeloma, standard risk, stage II.

Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.

Tanya Dorff, MD, asks the participants of a roundtable discussion what they would recommend as next-line therapy for a patient with nonmetastatic castration-resistant prostate cancer.

During a Targeted Oncology Case-Based Roundtable event, Melissa L. Johnson, MD, director, discussed the case of 66-year-old man with non–small cell lung cancer.

During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.

Tanya Dorff, MD, asks the participants of a roundtable discussion if they would order germline testing and molecular imaging in a patient with nonmetastatic castration-resistant prostate cancer.

A 77-year-old woman presented to her primary care physician with abdominal pain and fatigue.

After 8 months on enzalutamide, a patient with castration-resistant prostate cancer had a PSA level of 60.7 ng/mL. The abdominal/pelvic CT showed enlargement of known pelvic lymph nodes, and a bone scan showed progressive disease.

During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.

In a 73-year-old patient, a PET scan revealed activity in the left upper lobe mass, supraclavicular nodal areas, and liver lesions, and an MRI discovered 1 small asymptomatic brain lesion. This lead to a diagnosis of stage T3N3M1-IV extensive-stage small cell lung cancer.

A 78-year-old woman was diagnosed with stage II multiple myeloma and was deemed transplant ineligible.

Eight months after completion of adjuvant therapy for triple-negative breast cancer, a 48-year-old patient reported worsening fatigue.

A 59-year-old man with a history of smoking, hypertension, and osteoarthritis presented with chest pain, cough, and dyspnea.

A 51-year-old man who presented with pallor and worsening fatigue on exertion was diagnosed with standard risk, stage II multiple myeloma.

A 75-year-old man presented with intermittent right hip pain. The case was discussed between of physicians and moderated by Nauman Moazzam, MD.